Literature DB >> 7641204

Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization.

J Drach1, J Schuster, H Nowotny, J Angerler, F Rosenthal, M Fiegl, C Rothermundt, A Gsur, U Jäger, R Heinz.   

Abstract

Because metaphase cytogenetic studies in multiple myeloma (MM) are hampered by a low proliferative activity of myeloma cells in vitro, interphase cytogenetics by means of fluorescence in situ hybridization (FISH) should improve the detection of chromosomal abnormalities in MM. We therefore investigated chromosomal aneuploidy in 36 patients with MM using interphase FISH and alpha-satellite DNA probes for chromosomes 1, 3, 7, 8, 11, 12, 16, 17, 18, and X. By FISH, myeloma cells from 32 patients (88.9%) were aneuploid for at least one of the chromosomes examined. In 24 patients (66%), aberrations of > or = 3 chromosomes were observed. Aneuploidy was predominantly characterized by a gain of chromosome numbers, with involvement of chromosomes 3, 7, and 11 occurring in > 50% of patients. Loss of a centromeric signal suggesting monosomy was most frequently observed for chromosomes 17 (22.2% of patients) and X (monosomic in 42.3% of female patients, but loss of chromosome X was never observed in males, P < 0.05). Dual-color FISH studies provided evidence for marked heterogeneity of aneuploid cells in 8 patients (22.8%). Occurrence of chromosomal aneuploidy was independent of stage and pretreatment status. Gain of chromosome 3 was significantly correlated with an IgA paraprotein (P < 0.05). In 12 patients, the direct comparison of metaphase cytogenetics and FISH showed that FISH detected aneuploidy of chromosomes in 9 patients that was missed by metaphase analysis. In conclusion, interphase FISH, by which chromosomal aneuploidy was detected in almost 90% of patients with MM, represents an approach for evaluating the clinical significance of specific chromosomal abnormalities in MM.

Entities:  

Mesh:

Year:  1995        PMID: 7641204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH.

Authors:  Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Suppression of abnormal karyotype predicts superior survival in multiple myeloma.

Authors:  V Arzoumanian; A Hoering; J Sawyer; F van Rhee; C Bailey; J Gurley; J D Shaughnessy; E Anaissie; J Crowley; B Barlogie
Journal:  Leukemia       Date:  2008-01-17       Impact factor: 11.528

3.  Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.

Authors:  Xiao Gao; Chunming Li; Run Zhang; Ruifang Yang; Xiaoyan Qu; Hairong Qiu; Jiaren Xu; Hua Lu; Jianyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

Review 4.  Risk Stratification in Multiple Myeloma in Indian Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; A P Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-14       Impact factor: 0.900

5.  A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.

Authors:  Zhong Chen; Bonnie Issa; Shiang Huang; Emily Aston; Jia Xu; Margaret Yu; Arthur R Brothman; Martha Glenn
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

Review 6.  The Diagnosis and Treatment of Multiple Myeloma.

Authors:  Christian Gerecke; Stephan Fuhrmann; Susanne Strifler; Martin Schmidt-Hieber; Hermann Einsele; Stefan Knop
Journal:  Dtsch Arztebl Int       Date:  2016-07-11       Impact factor: 5.594

7.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

8.  CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities.

Authors:  R Avva; R L Vanhemert; B Barlogie; N Munshi; E J Angtuaco
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

Review 9.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

10.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.